Most Popular
-
1
Ador CEO denies allegations, accuses Hybe of mistreating NewJeans
-
2
Medical reform committee kicks off despite boycott from doctors
-
3
10-man S. Korea lose to Indonesia to miss out on Paris Olympic football qualification
-
4
DP leader says he will meet Yoon without conditions
-
5
Over 9,000 hotline calls made by stalking victims in 2023
-
6
[Hello India] Hyundai Motor vows to boost 'clean mobility' in India
![[Hello India] Hyundai Motor vows to boost 'clean mobility' in India](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/25/20240425050672_0.jpg&u=)
-
7
Hybe-Ador feud should have limited effect on Hybe's overall performance: analysts
-
8
Monthly users on local streaming platforms outpace Netflix, Disney+
-
9
US will take steps for three-way engagement on nuclear deterrence with S. Korea, Japan: Campbell
-
10
Second Gimpo civil servant found dead, after apologizing for not finishing work
![[Hello India] Hyundai Motor vows to boost 'clean mobility' in India](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/25/20240425050672_0.jpg&u=)
Samsung Bioepis to spend 180.4 bln won on new R&D center
By YonhapPublished : March 7, 2019 - 20:04
The investment cost accounts for 36.44 percent of the company's capital at the end of 2017, Samsung BioLogics, a biopharmaceutical unit of South Korea's top conglomerate Samsung Group, said in a regulatory filing.
"The construction of the R&D facility is intended to strengthen competitiveness," the company said.
Samsung Bioepis, which was established in 2012 in a joint venture between Samsung Biologics and Biogen Inc., mostly manufactures biosimilars.
The market for biosimilars has grown in recent years as such drugs are available to customers at a discount. Biosimilars are officially approved copycat medicines developed after patents for the original biopharmaceuticals expire. (Yonhap)
